Qu Biologics was issued U.S. Patent No. 8,501,198. The allowed claims relate to the use of E. coli components to stimulate an immune response to treat colon cancer. This latest patent follows Qu Biologics' first U.S. issued patent for the use of K. pneumoniae derived immunotherapies for the treatment of lung cancer.
Qu Biologics develops immunotherapies called Site Specific Immunomodulators (SSIs), which are derived from components of bacteria and are aimed at stimulating the body's immune system to treat cancer and immune-related disease. The company's SSI platform represents a promising new approach to the treatment of cancer and immune-related disease by addressing the immunological defect/deficiency that underlies these diseases. Qu Biologics has developed multiple SSIs, each of which targets a specific tissue/organ system (see also Clinical Trials and Studies).
Keywords for this news article include: Oncology, Escherichia, Immunotherapy, Immunomodulation, Enterobacteriaceae, Gammaproteobacteria, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- McDonald's Packages Coffee for National Distribution
- Apple Stock Bounces Back Big Time
- Castro-Blanco Joins Fifth Street Finance Board
- Google Kid Accounts Plan Raises Worries
- Target Slashes Annual Profit Outlook
- Ballmer Steps Down From Microsoft Board
- Honda's Safe Approach Pays Off in Sales
- Islamic Militant in James Foley Beheading Video May Be English
- HTC Makes Windows Version of Flagship One Phone
- GE Healthcare Bringing Jobs to Massachusetts